Published in J Am Soc Nephrol on March 01, 1999
Total nitric oxide production is low in patients with chronic renal disease. Kidney Int (2000) 2.11
Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol (2007) 1.53
Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol (2006) 1.40
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol (2008) 1.29
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant (2008) 1.15
Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag (2005) 1.10
Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci (2012) 0.99
Plasma from ESRD patients inhibits nitric oxide synthase activity in cultured human and bovine endothelial cells. Acta Physiol Scand (2000) 0.97
Plasma ADMA predicts restenosis of arteriovenous fistula. J Am Soc Nephrol (2008) 0.97
Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS One (2014) 0.95
Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol (2007) 0.95
Coronary artery calcification, ADMA, and insulin resistance in CKD patients. Clin J Am Soc Nephrol (2008) 0.93
Peripheral vascular dysfunction in chronic kidney disease. Cardiol Res Pract (2011) 0.92
Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol (2011) 0.90
[Atherosclerosis and uremia: signifance of non-traditional risk factors]. Wien Klin Wochenschr (2003) 0.86
L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. Mediators Inflamm (2012) 0.86
Regulation and prognostic relevance of symmetric dimethylarginine serum concentrations in critical illness and sepsis. Mediators Inflamm (2013) 0.85
Actin cytoskeleton modulates ADMA-induced NF-kappaB nuclear translocation and ICAM-1 expression in endothelial cells. Med Sci Monit (2011) 0.85
Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine. Int J Mol Sci (2012) 0.84
Carotid intima-media thickness and plasma asymmetric dimethylarginine in Mexican children exposed to inorganic arsenic. Environ Health Perspect (2013) 0.84
Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations. Pediatr Nephrol (2011) 0.83
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity. PLoS One (2012) 0.81
The inhibitory effect of quercetin on asymmetric dimethylarginine-induced apoptosis is mediated by the endoplasmic reticulum stress pathway in glomerular endothelial cells. Int J Mol Sci (2014) 0.80
Vasculoprotective Effects of Dietary Cocoa Flavanols in Patients on Hemodialysis: A Double-Blind, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol (2015) 0.80
Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. Nutr Metab (Lond) (2006) 0.79
Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts. Nephrol Dial Transplant (2010) 0.78
Serum asymmetric dimethylarginine (ADMA), homocysteine, vitamin B(12), folate levels, and lipid profiles in epileptic children treated with valproic acid. Eur J Pediatr (2010) 0.77
Asymmetric dimethylarginine is not elevated in exfoliation syndrome but symmetric dimethylarginine is related to exfoliative glaucoma. Graefes Arch Clin Exp Ophthalmol (2007) 0.77
Risk of cardiovascular diseases in diabetes mellitus and serum concentration of asymmetrical dimethylarginine. Biochem Res Int (2013) 0.76
Apolipoprotein E polymorphism modulation of asymmetric dimethylarginine in hypertensive patients is determined by renal function. Lipids Health Dis (2016) 0.76
eNOS Glu298Asp Polymorphism and Endothelial Dysfunction in Patients with and without End-stage Renal Disease. Balkan Med J (2016) 0.75
Pathophysiological, cardiovascular and neuroendocrine changes in hypertensive patients during the hemodialysis session. J Hum Hypertens (2014) 0.75
Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis. World J Gastroenterol (2016) 0.75
Effect of enzyme replacement therapy on serum asymmetric dimethylarginine levels, coronary flow reserve and left ventricular hypertrophy in patients with Fabry disease. Clin Kidney J (2012) 0.75
The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients. Clin Exp Nephrol (2012) 0.75
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 3.25
Urinary prostaglandins. Identification and origin. J Clin Invest (1975) 3.07
Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum (1997) 2.70
Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med (1978) 2.50
The three-dimensional structure of class pi glutathione S-transferase in complex with glutathione sulfonate at 2.3 A resolution. EMBO J (1991) 2.36
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation (1997) 2.20
Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant (1998) 2.15
Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med (2001) 2.00
Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum (1998) 1.86
Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res (1988) 1.77
LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res (2000) 1.76
Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells. Eur J Immunol (1989) 1.72
Suppression of plasma renin activity by indomethacin in man. Circ Res (1976) 1.62
Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation (1996) 1.61
Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) (2001) 1.59
Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med (1976) 1.55
Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest (2003) 1.49
Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) (1983) 1.47
The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol (2001) 1.46
Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant (1995) 1.45
Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther (2000) 1.44
Effect of changes in renal perfusion pressure on the suppression of proximal tubular sodium reabsorption due to saline loading. J Clin Invest (1969) 1.44
Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int (1996) 1.43
Treatment of hyperlipidemia in nephrotic syndrome: time for a change? Nephron (1992) 1.41
Effect of acute hypertension on sodium reabsorption by the proximal tubule. J Clin Invest (1968) 1.41
L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol (1998) 1.39
Colour Doppler ultrasound assessment of arteriovenous haemodialysis fistulas. Lancet (1992) 1.39
[Aspirin--yes, but 30 mg??]. Z Kardiol (1995) 1.39
Use of ibuprofen and methylprednisolone for the prevention of pain and swelling after removal of impacted third molars. J Oral Maxillofac Surg (1995) 1.36
Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res (1987) 1.35
Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett (2000) 1.29
Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int (1997) 1.25
Pulmonary hypertension correlated to pulmonary thromboxane synthesis. Adv Prostaglandin Thromboxane Res (1980) 1.25
Effect of dexamethasone on in vivo prostanoid production in the rabbit. J Clin Invest (1984) 1.24
Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature (1999) 1.23
Nitric oxide and inflammatory joint diseases. Br J Rheumatol (1998) 1.22
Metabolism of prostacyclin and 6-keto-prostaglandin F1 alpha in man. J Biol Chem (1980) 1.21
Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest (1995) 1.20
Extraction and chromatographic procedures for purification of prostaglandins, thromboxanes, prostacyclin, and their metabolites. Adv Prostaglandin Thromboxane Res (1978) 1.19
Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun (1996) 1.19
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol (2000) 1.17
Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood (1979) 1.16
L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond) (1994) 1.14
An outbreak of Achromobacter xylosoxidans related to diagnostic tracer procedures. Am J Epidemiol (1982) 1.14
Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int (1997) 1.11
Inhibitors of acyl-coenzyme A:lysolecithin acyltransferase activate the production of endothelium-derived vascular relaxing factor. J Pharmacol Exp Ther (1986) 1.10
An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol (2000) 1.10
[Intratubular pressure, glomerular capillary pressure and glomerular filtrate during mannitol diuresis]. Pflugers Arch Gesamte Physiol Menschen Tiere (1967) 1.07
[Intratubular pressure, glomerular capillary pressure and glomerular filtrate following furosemide and hydrochlorothiazide]. Pflugers Arch Gesamte Physiol Menschen Tiere (1967) 1.07
Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. J Pharmacol Exp Ther (1991) 1.06
Nitric oxide inhibits the secretion of T-helper 1- and T-helper 2-associated cytokines in activated human T cells. Immunology (1997) 1.05
Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol (1991) 1.05
L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation (1996) 1.05
Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation (1997) 1.04
The prostaglandin system. A role in canine baroreceptor control of renin release. Circ Res (1978) 1.03
Antidiuretic hormone increases renal prostaglandin synthesis in vivo. Am J Physiol (1978) 1.03
Prevention of postoperative swelling and pain by dexamethasone after operative removal of impacted third molar teeth. Eur J Clin Pharmacol (1993) 1.03
The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med (1978) 1.02
Indomethacin increases plasma lithium. Br Med J (1979) 1.01
N(G)-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atherosclerosis (1997) 1.01
Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis (1995) 1.01
Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant (2000) 1.01
Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest (1997) 1.01
Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat (2008) 1.01
Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest (1996) 1.00
Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest (2005) 1.00
Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol (1994) 1.00
Mechanisms of action of lipoxygenase and cytochrome P-450-mono-oxygenase inhibitors in blocking endothelium-dependent vasodilatation. Br J Pharmacol (1988) 1.00
Variations of recombinant human erythropoietin application in hemodialysis patients. Contrib Nephrol (1989) 0.99
Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int (1995) 0.99
Increased arachidonate in lipids after administration to man: effects on prostaglandin biosynthesis. Clin Pharmacol Ther (1975) 0.99
Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders. J Clin Invest (1993) 0.98
Enhancement of in-vitro human interleukin-1 production by sodium acetate. Lancet (1987) 0.98
Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. Kidney Int (1995) 0.98
Drug interactions with valproic acid. Drugs (1982) 0.98
Endothelium-derived relaxing factor influences renal vascular resistance. Am J Physiol (1990) 0.97
Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics. Clin Pharmacol Ther (1982) 0.97
Assessment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl (2000) 0.97
Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine (1995) 0.96
Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost (2000) 0.96
Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol (1998) 0.96
Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol (2001) 0.96
Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state. Eur J Clin Pharmacol (1983) 0.96
Studies on the ability of hemodialysis membranes to induce, bind, and clear human interleukin-1. J Lab Clin Med (1988) 0.95
Effects of diclofenac on lithium kinetics. Clin Pharmacol Ther (1981) 0.95
Regional differences in prostacyclin formation by the kidney. Prostacyclin is a major prostaglandin of renal cortex. Biochim Biophys Acta (1978) 0.95